Osimertinib is a third-generation EGFR-TKI targeted drug that selectively inhibits EGFR mutations (including T790M) to block tumor signaling pathways. It is mainly used for the treatment of EGFR mutation positive non-small cell lung cancer and has precise anti-tumor effects. It has been included in medical insurance.

1. Core mechanism of action

(1) Targeted inhibition: Specifically binds to EGFR mutant proteins (including exon 19 deletion, L858R, and T790M mutations), blocking tyrosine kinase activity.

(2) Signal blockade: interferes with the downstream signaling pathway of EGFR required for tumor cell proliferation and survival.

2. Main therapeutic effects

(1) Adjuvant therapy: Used for postoperative adjuvant therapy of EGFR mutation positive non-small cell lung cancer to reduce the risk of recurrence.

(2) Late stage treatment: shows significant survival benefits for patients with locally advanced/metastatic EGFR mutant NSCLC.

(3) Resistance reversal: Effective for EGFR-TKI resistant patients caused by T790M mutation.

3. Formulation characteristics

(1) Oral tablets: oval shaped film coated tablets, convenient for patients to take.

(2) Metabolic characteristics: Metabolized by liver CYP3A enzyme, attention should be paid to drug interactions.